On July 21, 2022, Oncoustics announced it had raised $5.5 million in its seed financing co-led by Creative Ventures and Saltagen Ventures, with participation from NorthSpring Capital Partners, Fraser Kearney Capital and Pallasite Ventures. With this all-equity round, Oncoustics plans to support the development of its products and fuel its work with the US Food and Drug Administration (FDA) in order to disrupt liver care by facilitating easier early disease detection, diagnosis and patient management.
Oncoustics is a Toronto and San Francisco-based startup that develops hardware-agnostic artificial intelligence to improve ultrasound devices and liver care across North America.
Osler, Hoskin & Harcourt LLP advised Oncoustics with a team consisting of David Jamieson and Dhananjay (DJ) Ghildyal (Emerging & High Growth Companies).